Loading...
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
BACKGROUND: New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. METHODS: We conducted a phase 1 do...
Na minha lista:
| Udgivet i: | N Engl J Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7107002/ https://ncbi.nlm.nih.gov/pubmed/26639348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1513257 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|